Robot-Assisted Transplantation of Hypoimmune iPSC Derived Dopaminergic Progenitor Cells for Idiopathic Parkinson’s Disease
Objective: This study aimed to evaluate the 12-month safety and preliminary efficacy of NCR201 transplantation in idiopathic PD patients, providing a proof-of-concept for universal cell…An Ongoing Phase 1/2, Multi-center, Open Label Study of NouvNeu001 for the Treatment of Advanced Parkinson’s Disease
Objective: This ongoing, phase 1/2, multi-center, open label study aims to evaluate the safety, tolerability, and efficacy of NouvNeu001 (NCT#06167681) for treating mid to late-stage…Robot-Assisted Transplantation of Hypoimmune iPSC-Derived Dopaminergic Progenitor Cells for PRKN-EOPD
Objective: This study aimed to evaluate the safety and preliminary efficacy of NCR201 transplantation in a PRKN-EOPD patient, providing a first proof-of-concept for this hypoimmune…L-DOPA Metabolism as a Function Related to the Potency of iPSC-Derived Dopaminergic Progenitor cells
Objective: This study aimed to elucidate how iPSC-derived dopaminergic progenitor cells (iPSC-DAPs) acquire the ability to metabolize L‑DOPA in vitro and to evaluate whether the…Continued Evaluation of Clinical Outcomes in Participants With Parkinson’s Disease Through 4 Years After Bemdaneprocel Administration
Objective: To report safety and clinical outcomes in participants with Parkinson’s disease (PD), 4 years after receiving bemdaneprocel. Background: Bemdaneprocel is an investigational cell therapy…Allogeneic iPSC-Derived Dopaminergic Progenitor Transplantation for Parkinson’s Disease: A Phase 1, Dose-Escalation Trial
Objective: To evaluate the safety, tolerability, and preliminary efficacy of putaminal implantation of XS411 (allogeneic iPSC-derived dopaminergic progenitors) in advanced PD (NCT07080775). Background: Parkinson’s disease (PD)…Paeoniflorin Combined with Neural Stem Cell Transplantation for Parkinson’s Disease: Synergistic Effects of Cell Therapy and Inflammation Regulation
Objective: To investigate the feasibility and efficacy of paeoniflorin (PF) combined with neural stem cell (NSC) transplantation in treating Parkinson's disease (PD). Background: Parkinson's disease…Safety, Tolerability, and Preliminary Efficacy of NouvNeu001 for the Treatment of Advanced Parkinson’s Disease: A Multi-center, Open Label, Phase 1 Study
Objective: This Phase 1 study aims to evaluate the safety, tolerability, preliminary efficacy, and optimal dose of NouvNeu001 for treating mid to late-stage Parkinson’s disease…Continued Evaluation of Bemdaneprocel Following a Phase 1 Study for Parkinson’s Disease: Outcomes Through 3 Years
Objective: To report the safety and clinical outcomes of bemdaneprocel in participants with Parkinson’s disease (PD) through 3 years post transplantation. Background: Bemdaneprocel is an…Targeting IGF2 Signaling for Immune Modulation of Microglia in Parkinson’s Disease
Objective: We propose that IGF2 induces a distinct inflammatory phenotype in macrophages or microglia derived from Parkinson’s disease (PD) patients. Background: Microglia are the resident…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.